Loading...

DP T

DP

EDAP TMS SA

(EDAP)

2025 6-K

Financing Update

2 Apr '26

Quarterly Results Announcement

25 Mar '26

Investor Conference Announc...

18 Mar '26

Board Changes

12 Feb '26

Preliminary Results

12 Jan '26

FDA Clearance Achieved

20 Nov '25

Filing Summary

18 Nov '25

EDAP TMS Q3 Results

6 Nov '25

Filing Overview

9 Sep '25

HIFU Reimbursement Secured

8 Sep '25

Strong Q2 Performance

28 Aug '25

Credit Facility Announcement

26 Aug '25

Reporting Status Change

1 Jul '25

Shareholders Meeting Notice

2 Jun '25

EDAP 6-K Filing

15 May '25

EDAP TMS Earnings

27 Mar '25

Board Appointment

3 Mar '25

Quarterly Sales Surge

13 Jan '25

Board Appointment

10 Jan '25

Positive Study Results

4 Dec '24

EDAP Q3 Results

7 Nov '24

EDAP Financial Results

28 Aug '24

HIFU Study Update

19 Jul '24

Board Appointment

8 Jul '24

Shareholder Meeting Notice

7 Jun '24

Strong Q1 Performance

16 May '24

Financial Results Announcement

27 Mar '24

FDA Breakthrough Designation

4 Mar '24

Management Changes

2 Jan '24

External Links:

SEC

EDAP TMS SA reported its 6-K filing on November 18, 2025, highlighting strong growth opportunities in the therapeutic ultrasound market, specifically for prostate cancer, with 3.3 million American men living with the disease. The company aims to meet the increasing demand for non-invasive treatments and has 76 Focal One systems installed in the U.S. as of September 30, 2025.

AI Assistant

EDAP TMS SA

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.